{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:52:34Z","timestamp":1781679154085,"version":"3.54.5"},"reference-count":21,"publisher":"Norwegian Medical Association","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2016,10,11]]},"DOI":"10.4045\/tidsskr.15.1356","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T08:40:44Z","timestamp":1476261644000},"page":"1543-6","source":"Crossref","is-referenced-by-count":3,"title":["New anticoagulants in combination with antiplatelet agents"],"prefix":"10.4045","volume":"136","author":[{"given":"Henriette","family":"Johansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole-Christian Walter","family":"Rutherford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-2760","authenticated-orcid":false,"given":"Anne Hege","family":"Aamodt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8793","authenticated-orcid":false,"given":"Dan","family":"Atar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Ghanima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","unstructured":"Vandvik PO. Retningslinjer for antitrombotisk behandling og profylakse. MagicApp: Norsk selskap for trombose og hemostase, 2013. Oppdatert 17.2.2015. www.magicapp.org\/app (23.2.2015)."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Kernan WN, Ovbiagele B, Black HR et al. Guide-lines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 2014; 45: 2160\u2009\u2013\u2009236. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24788967&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1161\/STR.0000000000000024","DOI":"10.1161\/STR.0000000000000024"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Lip GY, Windecker S, Huber K et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155\u2009\u2013\u200979. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25154388&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehu298","DOI":"10.1093\/eurheartj\/ehu298"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Camm AJ, Lip GY, De Caterina R et al 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation \u2013 developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385\u2009\u2013\u2009413. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22923145&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093\/europace\/eus305","DOI":"10.1093\/europace\/eus305"},{"key":"ref=5","unstructured":"Helsedirektoratet. Informasjon om warfarin og de nye perorale antikoagulasjonsmidlene dabigatran, rivaroksaban og apixaban. https:\/\/helsedirektoratet.no\/publikasjoner\/informasjon-om-warfarin-og-de-perorale-antikoagulasjonsmidlene-dabigatran-rivaroksaban-og-apixaban (23.6.2016)."},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139\u2009\u2013\u200951. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19717844&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa0905561","DOI":"10.1056\/NEJMoa0905561"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Hart RG, Diener HC, Yang S et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22492518&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1161\/STROKEAHA.112.650614","DOI":"10.1161\/STROKEAHA.112.650614"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Savelieva I, Camm AJ. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol 2014; 37: 32\u2009\u2013\u200947. . eng. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24254991&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/clc.22204","DOI":"10.1002\/clc.22204"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981\u2009\u2013\u200992. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21870978&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1107039","DOI":"10.1056\/NEJMoa1107039"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Alexander JH, Lopes RD, Thomas L et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2014; 35: 224\u2009\u2013\u200932. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24144788&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093\/eurheartj\/eht445","DOI":"10.1093\/eurheartj\/eht445"},{"key":"ref=11","unstructured":"Legeh\u00e5ndboka. Karotisstenose 2014. Oppdatert 1.11.2014. http:\/\/nevro.legehandboka.no\/handboken\/sykdommer\/cerebrovaskulare-sykdommer\/sykdommer-og-symptomer\/karotisstenose\/ (6.5.2015)."},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Whayne TF. A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol 2012; 21: 187\u2009\u2013\u200994. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24293975&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1055\/s-0032-1330232","DOI":"10.1055\/s-0032-1330232"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Windecker S, Kolh P, Alfonso F et al. 2014 ESC\/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed) 2015; 68: 144. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25623431&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.rec.2014.12.006","DOI":"10.1016\/j.rec.2014.12.006"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Lane DA, Raichand S, Moore D et al. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. Health Technol Assess 2013; 17: 1\u2009\u2013\u2009188. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23880057&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3310\/hta17300","DOI":"10.3310\/hta17300"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969\u2009\u2013\u200974. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12324552&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa020496","DOI":"10.1056\/NEJMoa020496"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699\u2009\u2013\u2009708. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21780946&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1105819","DOI":"10.1056\/NEJMoa1105819"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9\u2009\u2013\u200919. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22077192&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1112277","DOI":"10.1056\/NEJMoa1112277"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Ghanima W, Atar D, Sandset PM. Nye perorale antikoagulasjonsmidler \u2013 en oversikt. Tidsskr Nor Legeforen 2013; 133: 1940\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24084970&dopt=Abstract","DOI":"10.4045\/tidsskr.12.1111"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Davidson BL, Verheijen S, Lensing AW et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 2014; 174: 947\u2009\u2013\u200953. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24733305&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/jamainternmed.2014.946","DOI":"10.1001\/jamainternmed.2014.946"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Friedman RJ, Kurth A, Clemens A et al. Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding. Thromb Haemost 2012; 108: 183\u2009\u2013\u200990. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22552763&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1160\/TH11-08-0589","DOI":"10.1160\/TH11-08-0589"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955\u2009\u2013\u200962. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24315724&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0140-6736(13)62343-0","DOI":"10.1016\/S0140-6736(13)62343-0"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Nye antikoagulasjonsmidler i kombinasjon med platehemmere"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:56:16Z","timestamp":1781675776000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2016\/10\/klinisk-oversikt\/nye-antikoagulasjonsmidler-i-kombinasjon-med-platehemmere"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":21,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016,10,11]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.15.1356","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]}}}